| Dr Daniel John-martin Carroll, MD | |
|
7388 Business Center Dr, Avon, IN 46123-6973 | |
| (888) 938-3838 | |
| (888) 919-1083 |
| Full Name | Dr Daniel John-martin Carroll |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 11 Years |
| Location | 7388 Business Center Dr, Avon, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487093399 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 64776 (Minnesota) | Secondary |
| 207Y00000X | Otolaryngology | 01092672A (Indiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mankato Clinic Ltd | 5597677955 | 201 |
News Archive
In laboratory mouse experiments, researchers at The University of Texas M. D. Anderson Cancer Center have developed a way to use RNA interference (RNAi) so that it permanently hampers breast cancer development. The technique permanently silences activated STAT3, a crucial gene found in some human breast tumors, thus reducing the cancer's ability to become invasive.
(Garrison, NY) The latest issue of the Hastings Center Report features articles on "medicalized" weapons that temporarily incapacitate targets, sharing the benefits of newly found biological resources, and applications of GINA (the Genetic Information Nondisclosure Act).
Scott P. Serota, president and chief executive officer of the Blue Cross and Blue Shield Association (BCBSA), released the following statement regarding President Obama's address to the joint session of Congress:
The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.
› Verified 1 days ago
| Entity Name | Mankato Clinic Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629044029 PECOS PAC ID: 5597677955 Enrollment ID: O20031104000231 |
News Archive
In laboratory mouse experiments, researchers at The University of Texas M. D. Anderson Cancer Center have developed a way to use RNA interference (RNAi) so that it permanently hampers breast cancer development. The technique permanently silences activated STAT3, a crucial gene found in some human breast tumors, thus reducing the cancer's ability to become invasive.
(Garrison, NY) The latest issue of the Hastings Center Report features articles on "medicalized" weapons that temporarily incapacitate targets, sharing the benefits of newly found biological resources, and applications of GINA (the Genetic Information Nondisclosure Act).
Scott P. Serota, president and chief executive officer of the Blue Cross and Blue Shield Association (BCBSA), released the following statement regarding President Obama's address to the joint session of Congress:
The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.
› Verified 1 days ago
| Entity Name | Otolaryngology Head & Neck Surgery Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821195959 PECOS PAC ID: 1658268651 Enrollment ID: O20050118000086 |
News Archive
In laboratory mouse experiments, researchers at The University of Texas M. D. Anderson Cancer Center have developed a way to use RNA interference (RNAi) so that it permanently hampers breast cancer development. The technique permanently silences activated STAT3, a crucial gene found in some human breast tumors, thus reducing the cancer's ability to become invasive.
(Garrison, NY) The latest issue of the Hastings Center Report features articles on "medicalized" weapons that temporarily incapacitate targets, sharing the benefits of newly found biological resources, and applications of GINA (the Genetic Information Nondisclosure Act).
Scott P. Serota, president and chief executive officer of the Blue Cross and Blue Shield Association (BCBSA), released the following statement regarding President Obama's address to the joint session of Congress:
The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel John-martin Carroll, MD 10001 W Innovation Dr Ste 200, Milwaukee, WI 53226-4851 Ph: (888) 938-3838 | Dr Daniel John-martin Carroll, MD 7388 Business Center Dr, Avon, IN 46123-6973 Ph: (888) 938-3838 |
News Archive
In laboratory mouse experiments, researchers at The University of Texas M. D. Anderson Cancer Center have developed a way to use RNA interference (RNAi) so that it permanently hampers breast cancer development. The technique permanently silences activated STAT3, a crucial gene found in some human breast tumors, thus reducing the cancer's ability to become invasive.
(Garrison, NY) The latest issue of the Hastings Center Report features articles on "medicalized" weapons that temporarily incapacitate targets, sharing the benefits of newly found biological resources, and applications of GINA (the Genetic Information Nondisclosure Act).
Scott P. Serota, president and chief executive officer of the Blue Cross and Blue Shield Association (BCBSA), released the following statement regarding President Obama's address to the joint session of Congress:
The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.
› Verified 1 days ago
Dr. Valerie A Ball, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1115 North Ronald Reagan Parkway, Suite 225, Avon, IN 46123 Phone: 317-844-7059 Fax: 317-819-0044 | |
Dr. Michael W Myers, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1115 Ronald Reagan Pkwy, Suite 255, Avon, IN 46123 Phone: 317-844-7059 Fax: 317-819-0044 | |
Clement Joseph Mcdonald Iii, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1115 Ronald Reagan Pkwy, Ste 255, Avon, IN 46123 Phone: 317-217-2255 Fax: 317-819-0044 | |
David A Campbell, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1115 Ronald Reagan Pkwy, Avon, IN 46123 Phone: 317-944-6467 |